Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

Rhea-AI Summary

Marinus Pharmaceuticals, Inc. (MRNS) will release its financial results for Q4 and full year 2023 on March 5, 2024, followed by a conference call. The company focuses on developing therapeutics for seizure disorders.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on March 5, 2024. The Company will host a conference call at 4:30 p.m. E.T. on March 5, 2024, to provide a business update and discuss financial results.

Tuesday, March 5, 4:30 p.m. E.T.

Domestic: (888) 550-5280
International: (646) 960-0813
Webcast Registration: https://events.q4inc.com/attendee/513453609
Conference ID: 2696394

An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/events-and-presentations.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information about Marinus visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220631175/en/

Company Contacts

Investors

Jim DeNike

Senior Director, Investor Relations

Marinus Pharmaceuticals, Inc.

jdenike@marinuspharma.com

Media

Molly Cameron

Director, Corporate Communications & Investor Relations

Marinus Pharmaceuticals, Inc.

mcameron@marinuspharma.com

Source: Marinus Pharmaceuticals

FAQ

When will Marinus Pharmaceuticals release its financial results for Q4 and full year 2023?

Marinus Pharmaceuticals will release its financial results for Q4 and full year 2023 on March 5, 2024.

What time will the conference call to discuss financial results be held on March 5, 2024?

The conference call to discuss financial results will be held at 4:30 p.m. E.T. on March 5, 2024.

What is the focus area of Marinus Pharmaceuticals?

Marinus Pharmaceuticals is dedicated to developing innovative therapeutics to treat seizure disorders.